Indian Medicines Pharmaceutical Corp announces dividend of Rs 10 crore for stakeholders

New Delhi: Indian Medicines Pharmaceutical Corporation (IMPCL), a central public sector enterprise (CPSE), has announced to pay a dividend of Rs 10.13 crore to its stakeholders.

The dividend cheque of Rs 9.93 crore for the Ministry of Ayush was handed over to Union minister of Ayush Sarbananda Sonowal in a ceremony held at Transport Bhawan, on Thursday.

On this occasion, Sarbananda Sonowal said, “IMPCL has registered an impressive increase in its profits in comparison to the last Financial Year 2020-21, which is a commendable achievement. Under the visionary leadership of Prime Minister Narendra Modi, Ayush sector is witnessing all round growth not only in India but globally.”

Mukesh Kumar, MD, IMPCL, said, “In the operational front the company has achieved an enhancement of 47% in capacity utilisation over its previous year. An all-around enhancement in performance in terms of turnover, profit and capacity utilisation over previous years has brought focus on the future prospects of the company.”

IMPCL has been conferred mini ratna Category II status by the government of India and also got ISO 9001:2015 Certification. The company is presently manufacturing 656 classical avurvedic, 332 unand 71 proprietary ayurvedic medicines for the various diseases spectrum. It supplies ayurveda and unani medicines to all the states under National Ayush Mission (NAM) and 6,000 centres of Jan Aushadhi Kendras.

  • Related Posts

    • Pharma
    • June 22, 2024
    • 92 views
    Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

    New Delhi: Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India. The company has entered…

    • Pharma
    • June 22, 2024
    • 104 views
    Look-Alike, Sounding Similar Drugs Likely To Face Strict Action

    NEW DELHI: Have you ever got confused by similar looking or same sounding medicines? Here is some good news. Drug manufacturers may face strict action by the drug regulatory authority for…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

    Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

    Look-Alike, Sounding Similar Drugs Likely To Face Strict Action

    Look-Alike, Sounding Similar Drugs Likely To Face Strict Action

    Centre Forms 5-Member Panel To Examine Manufacturing Of Nutraceuticals Within Drug Production Facility

    Centre Forms 5-Member Panel To Examine Manufacturing Of Nutraceuticals Within Drug Production Facility

    Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

    Indian Pharmacopoeia Commission Flags ADR Linked To Meropenem

    Plan To Regulate Nutraceutical Industry Underway

    Plan To Regulate Nutraceutical Industry Underway

    Ayush And Herbal Products Exports Grow Over 20% In April

    Ayush And Herbal Products Exports Grow Over 20% In April